|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.17 - 0.18|
|52 Week Range||0.16 - 0.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.00|
Addition of CA4P simultaneously reduces tumor volume and increases tumor white blood cells, T Cells and cytotoxic T Cells compared to anti-CTLA-4 monotherapy Preliminary data suggest immuno-oncology applications ...
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2017-- Mateon Therapeutics, Inc., a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today provided a corporate ...
New Data Continue to Show OXi4503 has Significant Potential as New Treatment for AML OXi4503 Recently Prioritized as Lead Drug Development Program at Mateon SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017-- ...
Company to terminate FOCUS study due to lack of clear efficacy signal in the third interim analysis Company to reduce headcount, concentrate on OXi4503 for acute myeloid leukemia. SOUTH SAN FRANCISCO, ...
Zacks.com featured highlights: Mateon Therapeutics, Emerge Energy Services, Cobalt International Energy and Inpixon